210 related articles for article (PubMed ID: 22027689)
1. MUC13 mucin augments pancreatic tumorigenesis.
Chauhan SC; Ebeling MC; Maher DM; Koch MD; Watanabe A; Aburatani H; Lio Y; Jaggi M
Mol Cancer Ther; 2012 Jan; 11(1):24-33. PubMed ID: 22027689
[TBL] [Abstract][Full Text] [Related]
2. Expression and functions of transmembrane mucin MUC13 in ovarian cancer.
Chauhan SC; Vannatta K; Ebeling MC; Vinayek N; Watanabe A; Pandey KK; Bell MC; Koch MD; Aburatani H; Lio Y; Jaggi M
Cancer Res; 2009 Feb; 69(3):765-74. PubMed ID: 19176398
[TBL] [Abstract][Full Text] [Related]
3. MUC13 interaction with receptor tyrosine kinase HER2 drives pancreatic ductal adenocarcinoma progression.
Khan S; Sikander M; Ebeling MC; Ganju A; Kumari S; Yallapu MM; Hafeez BB; Ise T; Nagata S; Zafar N; Behrman SW; Wan JY; Ghimire HM; Sahay P; Pradhan P; Chauhan SC; Jaggi M
Oncogene; 2017 Jan; 36(4):491-500. PubMed ID: 27321183
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-145 targets MUC13 and suppresses growth and invasion of pancreatic cancer.
Khan S; Ebeling MC; Zaman MS; Sikander M; Yallapu MM; Chauhan N; Yacoubian AM; Behrman SW; Zafar N; Kumar D; Thompson PA; Jaggi M; Chauhan SC
Oncotarget; 2014 Sep; 5(17):7599-609. PubMed ID: 25277192
[TBL] [Abstract][Full Text] [Related]
5. MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways.
Tiemin P; Fanzheng M; Peng X; Jihua H; Ruipeng S; Yaliang L; Yan W; Junlin X; Qingfu L; Zhefeng H; Jian L; Zihao G; Guoxing L; Boshi S; Ming Z; Qinghui M; Desen L; Lianxin L
J Hepatol; 2020 Apr; 72(4):761-773. PubMed ID: 31837357
[TBL] [Abstract][Full Text] [Related]
6. Reduction of miR‑132‑3p contributes to gastric cancer proliferation by targeting MUC13.
He L; Qu L; Wei L; Chen Y; Suo J
Mol Med Rep; 2017 May; 15(5):3055-3061. PubMed ID: 28339011
[TBL] [Abstract][Full Text] [Related]
7. MUC4 mucin potentiates pancreatic tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins.
Chaturvedi P; Singh AP; Moniaux N; Senapati S; Chakraborty S; Meza JL; Batra SK
Mol Cancer Res; 2007 Apr; 5(4):309-20. PubMed ID: 17406026
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of mucin 13 due to promoter methylation promotes aggressive behavior in ovarian cancer cells.
Sung HY; Park AK; Ju W; Ahn JH
Yonsei Med J; 2014 Sep; 55(5):1206-13. PubMed ID: 25048476
[TBL] [Abstract][Full Text] [Related]
9. Functions and regulation of MUC13 mucin in colon cancer cells.
Gupta BK; Maher DM; Ebeling MC; Stephenson PD; Puumala SE; Koch MR; Aburatani H; Jaggi M; Chauhan SC
J Gastroenterol; 2014 Oct; 49(10):1378-91. PubMed ID: 24097071
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of MUC13 in pancreatic ductal adenocarcinoma.
Khan S; Zafar N; Khan SS; Setua S; Behrman SW; Stiles ZE; Yallapu MM; Sahay P; Ghimire H; Ise T; Nagata S; Wang L; Wan JY; Pradhan P; Jaggi M; Chauhan SC
HPB (Oxford); 2018 Jun; 20(6):563-572. PubMed ID: 29352660
[TBL] [Abstract][Full Text] [Related]
11. High mobility group AT-hook 1 (HMGA1) is an independent prognostic factor and novel therapeutic target in pancreatic adenocarcinoma.
Liau SS; Rocha F; Matros E; Redston M; Whang E
Cancer; 2008 Jul; 113(2):302-14. PubMed ID: 18473350
[TBL] [Abstract][Full Text] [Related]
12. S100A4 promotes pancreatic cancer progression through a dual signaling pathway mediated by Src and focal adhesion kinase.
Che P; Yang Y; Han X; Hu M; Sellers JC; Londono-Joshi AI; Cai GQ; Buchsbaum DJ; Christein JD; Tang Q; Chen D; Li Q; Grizzle WE; Lu YY; Ding Q
Sci Rep; 2015 Feb; 5():8453. PubMed ID: 25677816
[TBL] [Abstract][Full Text] [Related]
13. Increased expression and aberrant localization of mucin 13 in metastatic colon cancer.
Gupta BK; Maher DM; Ebeling MC; Sundram V; Koch MD; Lynch DW; Bohlmeyer T; Watanabe A; Aburatani H; Puumala SE; Jaggi M; Chauhan SC
J Histochem Cytochem; 2012 Nov; 60(11):822-31. PubMed ID: 22914648
[TBL] [Abstract][Full Text] [Related]
14. A Rac-Pak signaling pathway is essential for ErbB2-mediated transformation of human breast epithelial cancer cells.
Arias-Romero LE; Villamar-Cruz O; Pacheco A; Kosoff R; Huang M; Muthuswamy SK; Chernoff J
Oncogene; 2010 Oct; 29(43):5839-49. PubMed ID: 20711231
[TBL] [Abstract][Full Text] [Related]
15. P21-activated kinase 1 stimulates colon cancer cell growth and migration/invasion via ERK- and AKT-dependent pathways.
Huynh N; Liu KH; Baldwin GS; He H
Biochim Biophys Acta; 2010 Sep; 1803(9):1106-13. PubMed ID: 20595063
[TBL] [Abstract][Full Text] [Related]
16. A newly developed anti-Mucin 13 monoclonal antibody targets pancreatic ductal adenocarcinoma cells.
Nishii Y; Yamaguchi M; Kimura Y; Hasegawa T; Aburatani H; Uchida H; Hirata K; Sakuma Y
Int J Oncol; 2015 Apr; 46(4):1781-7. PubMed ID: 25672256
[TBL] [Abstract][Full Text] [Related]
17. Blockage of PAK1 alleviates the proliferation and invasion of NSCLC cells via inhibiting ERK and AKT signaling activity.
Song P; Song B; Liu J; Wang X; Nan X; Wang J
Clin Transl Oncol; 2021 Apr; 23(4):892-901. PubMed ID: 32974862
[TBL] [Abstract][Full Text] [Related]
18. Biophysical changes caused by altered MUC13 expression in pancreatic cancer cells.
Massey AE; Doxtater KA; Yallapu MM; Chauhan SC
Micron; 2020 Mar; 130():102822. PubMed ID: 31927412
[TBL] [Abstract][Full Text] [Related]
19. B7-H4 enhances oncogenicity and inhibits apoptosis in pancreatic cancer cells.
Qian Y; Hong B; Shen L; Wu Z; Yao H; Zhang L
Cell Tissue Res; 2013 Jul; 353(1):139-51. PubMed ID: 23660627
[TBL] [Abstract][Full Text] [Related]
20. S100A4, frequently overexpressed in various human cancers, accelerates cell motility in pancreatic cancer cells.
Sekine H; Chen N; Sato K; Saiki Y; Yoshino Y; Umetsu Y; Jin G; Nagase H; Gu Z; Fukushige S; Sunamura M; Horii A
Biochem Biophys Res Commun; 2012 Dec; 429(3-4):214-9. PubMed ID: 23085231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
